Tag Archives: targets

SPRINT, ESPRIT and BPROAD were three large RCTs with 9,361, 11,255 and 12,821 participants, respectively, that support a more intensive SBP target closer to 120 mmHg.5–7 These trials recruited patients ≥50 years old at high cardiovascular risk with SBP 130–180 mmHg.5–7 The primary composite outcome in all three trials focused on similar major cardiovascular outcomes: myocardial infarction, acute coronary syndrome not resulting in myocardial infarction, coronary or non-coronary revascularisation, stroke, decompensated heart failure or death from cardiovascular causes. The mean SBP achieved in SPRINT, ESPRIT and BPROAD trials (intensive

The Gospel of Matthew tells us, “…the last can be first…” Nowhere is this truer than the towering UK success of that fundamental cornerstone of cardiovascular prevention, cholesterol-lowering therapy. In 2002, BJC published a paper showing how far the UK lagged behind other countries in Europe when it came to prescribing lipid-lowering drugs.1 At the same time, a number of other very large UK surveys were published.2 All showed that the UK was the sick man of Europe, with limited statin prescribing in the face of a huge burden of cardiovascular disease. Figure 1. Coronary heart disease (CHD) mortality compared to statin sales: Aug

Dr Gilbert Wagener (Transcrip Partners LLP) Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a new target for the treatment of hyperlipidaemia. PCSK9 is apparently complimentary to 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibition with statins.6,7 Most advanced in the development path are two monoclonal antibodies (mAbs) against PCSK9, alirocumab (SAR236533) and evolocumab (AMG145), both subcutaneous injectable drugs administered at bi-weekly or four-weekly intervals. Both compounds demonstrated solid reductions in LDL-C, however, dose selection for both focused on the most effective dose and did not consider titration ac

No content available